At a glance
What is it—and why does it matter?
Mechanistically, desmopressin acetate acts as a V2 receptor agonist in the kidney, promoting water reabsorption and thereby decreasing urine production. In this postpartum period, desmopressin discontinuation coincided with spontaneous symptom resolution while copeptin remained normal. The source lists specific contraindicated risk groups for severe hyponatremia with desmopressin acetate: excessive fluid intake, certain intercurrent illnesses affecting fluid/electrolyte balance, and concomitant loop diuretics or systemic/inhaled glucocorticoids.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Nocturia, central diabetes insipidus, and bleeding-disorder uses belong to different products and routes; they must not be collapsed into one generic instruction set. [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
Identity + structure
A molecule, not a product name.
| Preferred name | Desmopressin | Ingredient |
|---|---|---|
| Pharmacologic class | Vasopressin analog | Profile record |
| Peptide structure | 9 amino acids | Profile record |
| Also indexed as | desmopressin · desmopressin acetate · DDAVP · 1-deamino-8-D-arginine vasopressin | Search aliases |
Mechanism + clinical pharmacology
Target, response, and disposition.
Renal V2 receptor activation inserts aquaporin-2 water channels in collecting ducts; endothelial V2 signaling releases von Willebrand factor and factor VIII. [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
The authors’ overall conclusion was that preprocedural desmopressin did not reduce bleeding odds when considering all included studies together, noting high between-group heterogeneity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this case series, discontinuation of desmopressin was followed by maintenance of stable water balance, without recurrence of polyuria or clinically significant hypernatremia during follow-up.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Outcome assessment focused on intraoperative blood loss volume and surgical field quality, operationalizing a clean field as Boezaart grading system score ≤2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Unlike total AQP2 and pS256-AQP2, pS269-AQP2 showed predominant apical membrane localization in renal collecting duct cells independent of dDAVP treatment and hydration status.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this single-patient case report, a therapeutic trial of desmopressin led to symptomatic improvement, which was used as supportive evidence for central diabetes insipidus (a disorder of arginine vasopressin deficiency).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin increases plasma factor VIII activity in hemophilia and von Willebrand’s disease Type I.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The trial objective was to assess the effect of intranasal desmopressin premedication on intraoperative bleeding volume and surgical field quality during FESS.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an ex vivo human precision-cut kidney slice model, 30 min exposure to desmopressin (dDAVP) was associated with apical-membrane accumulation of aquaporin-2 (AQP2) in medullary slices, consistent with preserved short-term AQP2 trafficking/signaling in this tissue context.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Route-specific subgroup pooling estimated the odds of total bleeding with intranasal preprocedural desmopressin as OR 0.68 (0.30 to 1.56).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Reducing desmopressin from 10 µg to 4 µg under fluid restriction was associated with a slightly lower median ACTH at +15 min (4.4 vs 4.9 pmol/L), with P = 0.06.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Clinical trial outcome reported for hemophilia A: in two outpatient trials with patient-recorded bleeding episodes, 2/5 patients achieved effective hemostasis in all recorded bleeding occasions with STIMATE.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a rat hydration model, single-dose treatment with desmopressin (dDAVP) produced the most pronounced increase in uEV pS269-AQP2 relative to total AQP2 (phosphorylated + nonphosphorylated) and uEV pS256-AQP2.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Effectiveness was defined by a quantitative imaging-based threshold: hematoma expansion ≥ 3 mL over the first day of hospitalization.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the reported trial results, desmopressin was associated with lower intraoperative blood loss during the second hour than placebo, with the given estimates and P value.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Post-treatment relapse at 1 month was higher in the desmopressin arm than the mirabegron arm, with a statistically significant difference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The trial results report a lower total transfusion volume in the desmopressin arm compared with placebo, including the reported values and P value.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this retrospective comparison, DDAVP exposure was associated with lower odds of hematoma expansion over the first 24 hours, with an odds ratio of 0.22 and a p value of 0.002.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adding dexamethasone 1 mg before 10 µg desmopressin (with fluid restriction) was associated with lower median ACTH and cortisol values throughout the test compared with the standard 10 µg desmopressin with fluid restriction protocol in healthy volunteers.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In rats undergoing a hydration model, single-dose exposure to desmopressin (a synthetic AVP analog) was associated with the largest rise in urinary extracellular vesicle pS269-AQP2 relative to total AQP2 and pS256-AQP2, suggesting a strong AVP-linked response of the pS269-phosphorylated AQP2 species in uEVs.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In healthy volunteers, desmopressin produced small absolute rises in ACTH and cortisol; because baselines can be low, these translate into large percentage (relative) changes.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose–response studies in diabetes insipidus reported clinically significant antidiuresis with oral desmopressin acetate across 0.025–0.4 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In central (cranial) diabetes insipidus, desmopressin acetate injection is indicated to replace antidiuretic hormone activity (antidiuretic replacement therapy).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source explicitly states lack of efficacy for nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The results report a lower proportion with intraoperative packed red blood cell transfusions in the desmopressin group versus placebo, with the stated percentages and P value.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In central diabetes insipidus (arginine vasopressin deficiency), desmopressin is used as first-line therapy to replace deficient antidiuretic hormone activity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Route-specific pooling found higher odds of total bleeding with intravenous preprocedural desmopressin (OR 1.47; 1.05 to 2.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In healthy volunteers at +15 minutes, lowering the desmopressin dose from 10 µg to 4 µg (both with fluid restriction) corresponded to a lower median ACTH (4.4 vs 4.9 pmol/L; P = 0.06).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A clinical evaluation assessed both efficacy and tolerability of perorally administered desmopressin in adults with central diabetes insipidus.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacodynamic effects in central diabetes insipidus: decreased urinary output with increased urine osmolality and decreased plasma osmolality.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
By 5 min post-stimulation in IPSS, the average ACTH ratio increase was 2.7X for either desmopressin or CRH.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A leave-one-out sensitivity analysis yielded a revised pooled estimate for intranasal preprocedural desmopressin: OR 0.42 (0.31 to 0.59) for total bleeding.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Despite persistent radiologic absence of the posterior pituitary bright spot at admission, all five chronic-phase post-traumatic AVP-D cases were able to taper off and discontinue desmopressin under care.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When response interpretation used an absolute ACTH rise threshold (>8.1 pmol/L (37 pg/mL)) rather than relative changes, specificity reached 100% across all desmopressin stimulation test protocols studied in healthy volunteers.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Typical optimal antidiuresis in most patients was achieved at 0.1–0.2 mg oral dosing, with duration reported up to 8 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This case report states that intravenous desmopressin was an effective treatment during a suspected transient phase of adipsic arginine vasopressin deficiency, with resolution before hospital discharge.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In cortical human precision-cut kidney slices (ex vivo), aquaporin-2 (AQP2) displayed substantial apical localization under baseline conditions, indicating pre-existing apical positioning in this tissue preparation.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Sequential dynamic testing—water deprivation followed by desmopressin challenge—was sufficient to reach a definitive diagnostic classification in this cohort.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For central diabetes insipidus, desmopressin nasal spray is stated to decrease urine output while increasing urine osmolality and decreasing plasma osmolality.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
AUC summarizes diagnostic discrimination in this cohort; it does not by itself specify the best cutoff or generalize beyond the studied setting.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For the desmopressin stimulation test in healthy volunteers, defining a “positive” response by relative hormone increases (ACTH 35% and/or cortisol 20%) produced limited specificity, ranging from 50% (10 µg with fluid restriction) to 85% (10 µg with 1 mg dexamethasone pre-treatment under fluid restriction).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The results state there was no significant between-group difference in hemodynamic stability or hospital stay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within a dehydration/hydration model (rat), the level of pS269-AQP2 in urinary extracellular vesicles tracked closely with urinary indices—osmolality and electrolyte concentrations—supporting its linkage to changes in urine concentrating and electrolyte status in that model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For the 10 µg desmopressin protocol preceded by dexamethasone 1 mg (with fluid restriction), applying relative-increase criteria (ACTH 35% and/or cortisol 20%) resulted in specificity of 85% (95% CI: 69-100%) in healthy volunteers.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this postpartum period, desmopressin discontinuation coincided with spontaneous symptom resolution while copeptin remained normal.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In hemophilia and Type I von Willebrand’s disease, desmopressin increases plasma factor VIII activity levels.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In indicated bleeding disorders, desmopressin increases plasma factor VIII activity levels.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Route-specific subgroup pooling found lower odds of total bleeding with subcutaneous preprocedural desmopressin (OR 0.37; 0.21 to 0.65).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a desmopressin stimulation test in healthy volunteers (10 µg with fluid restriction), interpreting responses by relative ACTH and/or cortisol increases (35% and/or 20%) produced low diagnostic specificity: 50% (95% CI: 28-72%).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this case, the adjuvant chemotherapy course proceeded to completion of four planned cycles.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In healthy volunteers at +15 minutes, a lower desmopressin dose (4 µg with fluid restriction) was associated with lower median cortisol than 10 µg with fluid restriction (248 vs 284 nmol/L; P = 0.01).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Lowering the desmopressin dose to 4 µg under fluid restriction produced a lower median cortisol at +15 min (248 vs 284 nmol/L), with P = 0.01.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In patients with hemophilia and type I von Willebrand’s disease, desmopressin acetate is stated to raise plasma factor VIII activity levels.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this randomized trial, desmopressin was associated with lower first-hour intraoperative blood loss than placebo, with the reported group values and P value.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
It does not work for nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In DDAVP-stimulated BIPSS, the maximal IPS:P ratio was most commonly observed shortly after stimulation (3–5 minutes), informing sampling timepoints.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort, DDAVP stimulation during BIPSS produced very high diagnostic discrimination (AUC 0.994) between Cushing disease and ectopic ACTH syndrome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 30 minutes post-dose under isoflurane anesthesia, DDAVP at 1.2 and 1.8 µg/kg significantly reduced BMBT versus saline control, indicating improved primary hemostasis on this assay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In pediatric central diabetes insipidus, desmopressin is described as the first-line therapeutic agent for management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the dehydration/hydration model, total AQP2 measured in urinary extracellular vesicles showed no statistically significant correlation with urinary osmolality or electrolyte concentrations, distinguishing total AQP2 from phosphorylated forms in this context.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using a responder definition of at least 90% reduction in wet nights, desmopressin achieved a 46.5% full response rate in this trial.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
In the oldest group (aged ≥ 90 years), prescribing favored 25 μg relative to 50 μg, with a 25 μg/50 μg ratio of 1.37.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using a > 3X post-stimulation ACTH ratio criterion, 51/57 (89%) responded with desmopressin stimulation and 33/36 (91.7%) responded with CRH stimulation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study compared traditional vs ROC-optimized IPS:P ratio cutoffs for DDAVP-stimulated BIPSS.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Standard bioequivalence methodology often evaluates log-transformed PK metrics and checks whether the 90% CI for the test/reference geometric mean ratio lies within prespecified bounds (here 80%–125%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cohort sizes for desmopressin formulation groups are explicitly provided, enabling comparison between MELT and tablet groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The exposure definition was DDAVP administered when the hemorrhage was recognized, compared with not receiving DDAVP.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Lower cutoffs raised sensitivity to 97.4% while specificity stayed 100.0%.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Bioequivalence testing compares systemic exposure between formulations; here, an oral solution (50 mcg/mL) was compared with 200 mcg tablets in healthy adults.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Usability domains (management, preparation, administration, cleanup) for desmopressin ODTs were assessed using a bipolar 11-point scale anchored from - 50 to + 50 relative to conventional powder formulations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A comparative assessment was performed of IPSS stimulation responses using desmopressin versus CRH in Cushing’s Disease.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Switching from injection to nasal spray: use 10 times the injection amount (round down to the nearest 10 mcg).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Mechanism
Source-backed statements about targets, pathways, and biological response.
Desmopressin produces antidiuresis via V2 receptor stimulation in the kidney, increasing water reabsorption and decreasing urine output.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In human receptor assays, desmopressin is classified as a full agonist at the V1A receptor, with binding affinity reported as pKi 7.0 - 7.7.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the renal collecting duct, AVP receptor 2 activation is linked to phosphorylation of the AQP2 C-terminus; this phosphorylation promotes AQP2 trafficking (translocation) to the apical membrane, which increases water reabsorption.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin bound the human vasopressin V2 receptor with Ki = 5.0 nM (CHO membrane assay).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source characterizes pediatric central diabetes insipidus as resulting from deficiency of the antidiuretic hormone arginine vasopressin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source characterizes desmopressin’s pharmacologic role as antidiuretic, affecting renal water conservation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The paper reports that a two-parameter kinetic model for iodine-mediated intramolecular S–S bond formation predicts optimal iodine stoichiometry and aligns well with experimental results for desmopressin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a receptor binding assay using plasma membranes from CHO cells stably transfected with VP/OT receptors, desmopressin showed Ki = 5.0 nM at the human vasopressin V2 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin bound the human vasopressin V1b receptor with Ki = 0.37 nM (CHO membrane assay).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin’s antidiuretic action is mediated through vasopressin V2 receptor stimulation, which increases renal water reabsorption and thereby lowers urine production.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
In HEK293 cells expressing human vasopressin V2, CHEMBL1429 produced agonist activity with an EC50 of 0.2 nM measured after 5 hrs using a firefly luciferase reporter gene assay, quantifying potency for receptor activation in this cell-based system.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
In human receptor assays, desmopressin is classified as a full agonist at the OT receptor, with binding affinity reported as pKi 6.7 - 7.6.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By activating V2 receptors in the kidney, desmopressin increases water reabsorption, producing an antidiuretic effect that lowers urine volume.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin reduces urine production by stimulating V2 receptors to increase kidney water reabsorption.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a vasopressin analogue, desmopressin activates renal V2 receptors to promote water reabsorption, producing antidiuresis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In patients with hemophilia and type I von Willebrand disease, desmopressin is stated to raise plasma factor VIII activity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin’s hydrogen-suppressed molecular graph was included in a comparative, graph-theoretic resilience analysis to test whether new connectivity-based descriptors generalize across cyclic peptides.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A generalized linear mixed model was applied to evaluate associations between HRT exposure and organ donation outcomes in an adult CBI cohort.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In human receptor assays, desmopressin is classified as a full agonist at the V1B receptor, with binding affinity reported as pKi 7.7 - 8.2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In renal collecting duct cells (rat), pS269-phosphorylated AQP2 was reported to localize predominantly to the apical membrane and this localization did not vary with desmopressin (dDAVP) treatment or hydration status, implying relative stability of cellular distribution for this phosphorylated form under the tested conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanistically, desmopressin’s antidiuretic action is attributed to V2 receptor stimulation, which increases renal water reabsorption and thereby reduces urine production.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In human receptor assays, desmopressin is classified as a full agonist at the V2 receptor, with binding affinity reported as pKi 7.2 - 8.6.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using plasma membranes from CHO cells stably transfected with VP/OT receptors, CHEMBL1429 had a measured Ki of 5.0 nM at the human vasopressin V2 receptor, reflecting its in vitro binding affinity under these assay conditions.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanistically, desmopressin acetate acts as a V2 receptor agonist in the kidney, promoting water reabsorption and thereby decreasing urine production.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
In HEK293 cells expressing human V2, desmopressin had EC50 = 0.2 nM after 5 hrs in a luciferase reporter assay.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated mechanism is receptor-mediated: desmopressin’s primary pharmacodynamic action is binding to vasopressin 2 (V2) receptors, which are involved in renal water handling.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A structure-activity change from arginine vasopressin to desmopressin acetate is stated to reduce vasopressor and visceral smooth muscle effects while enhancing antidiuretic activity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a firefly luciferase reporter gene assay measured after 5 hrs in CHO-K1 cells expressing the human oxytocin receptor, desmopressin showed EC50 = 72.0 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a luciferase reporter gene assay measured after 5 hrs in HEK293 cells expressing recombinant human V1B, desmopressin showed EC50 = 11.0 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate acts on vasopressin 2 (V2) receptors in the kidney, increasing water reabsorption and thereby decreasing urine output (antidiuresis).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
The primary excretion route reported for desmopressin acetate is renal (urinary) excretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Human pharmacokinetic data after intravenous dosing report a desmopressin half-life (T1/2) of 3.0 hr.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Systemic elimination shows a geometric mean terminal half-life of 2.8 hours, reflecting the typical terminal phase of desmopressin concentration decline.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal impairment prolongs desmopressin terminal half-life; the reported geometric mean values rise stepwise from 2.8 hours (normal renal function) to 8.7 hours (severe impairment) in a 24-subject study with 6 per group.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The renal-impairment PK study (single 2 mcg injection) reports increased mean exposure by severity category relative to normal renal function.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal impairment increases desmopressin systemic persistence and exposure after a 2 mcg injected dose, with higher terminal half-life and higher mean exposure in severe impairment versus normal renal function.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal excretion is substantial: following 2 mcg IV dosing, 52% of desmopressin is recovered in urine over 24 hours without metabolic change.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After intranasal administration, desmopressin acetate shows a two-phase elimination pattern with a rapid and a slower half-life component.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This was a single-dose injection pharmacokinetic study with 6 subjects in each renal function group; it may not reflect intranasal dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Time-course of pharmacodynamic effect for oral tablets is described with onset ~1 hour and maximal effect at ~4–7 hours, using urine osmolality as the measurement basis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For STIMATE given intranasally as a 1.5 mg/mL solution, the labeling reports absolute bioavailability ranging from 3.3 to 4.1 percent.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A human pharmacokinetic measurement reports an elimination half-life (T1/2) of 3.0 hr for CHEMBL1429 after intravenous administration, representing the time for concentration to decline by half under the stated conditions.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Following a 2 mcg intravenous dose, about half the administered desmopressin (52%) is excreted unchanged in urine over 24 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In these data, desmopressin exhibited monoexponential elimination with a dose-independent terminal half-life range of 1.5–2.5 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In an in vitro proteolytic stability assay, desmopressin showed an alpha-chymotrypsin degradation half-life (T1/2) of 0.2167 hr.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Following intraintestinal administration in rats, desmopressin peak concentration (Cmax) was reported as 0.7482 nM.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A pharmacokinetic study (n=24; 6 per group) reported longer terminal half-life with worsening renal function (3 hours normal vs 9 hours severe renal impairment) after single-dose 2mcg injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The absorption phase is described with a Tmax of approximately 40 to 45 minutes following intranasal STIMATE dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The absorption section reports a Tmax of approximately 40 to 45 minutes after dosing for desmopressin acetate with STIMATE.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
An excretion statement reports that following a 2 mcg intravenous dose, about half the dose (52%) is recovered in urine within 24 hours as unchanged drug.
4 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 4 source records.
Relative bioavailability for the oral tablet is low, estimated at ~5% versus intranasal and ~0.16% versus IV administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The primary excretion route described is renal (urinary) excretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling reports increased systemic exposure (AUC) with worsening renal impairment (mild/moderate/severe) compared with normal renal function in a 2 mcg IV pharmacokinetic study.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A rat pharmacokinetic entry reports an intravenous half-life (T1/2) of 0.65 hr for CHEMBL1429, indicating rapid elimination in this species under the described study condition.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Elimination occurs in two phases: a rapid initial phase (t1/2 7.8 minutes) and a slower terminal phase (t1/2 75.5 minutes).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Elimination occurs in two phases, with a short initial half-life and a longer terminal half-life (7.8 and 75.5 minutes).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Human PK: after single-dose oral DESMODA 0.6 mg in healthy subjects, peak plasma concentration and overall exposure were quantified as mean (SD) Cmax 82 (33) pg/mL and mean (SD) total systemic exposure 314 (138) (hrs∙pg/mL).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A human pharmacokinetic measurement reported a steady-state volume of distribution (Vdss) of 0.3 L.kg-1 for CHEMBL1429 following intravenous administration, describing the extent of distribution in the body at steady state.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In healthy people given a single 0.6 mg oral dose, mean Cmax (SD) was 82 (33) pg/mL and mean total exposure (SD) was 314 (138) (hrs∙pg/mL).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
An in vitro degradation assay reports that CHEMBL1429 has a half-life (T1/2) of 0.2167 hr when exposed to alpha-chymotrypsin, indicating susceptibility to proteolytic breakdown in this enzyme system.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The pharmacokinetics section states biphasic elimination, reporting two half-lives corresponding to initial and terminal phases.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The primary excretion route described for desmopressin acetate is urinary excretion.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Urinary excretion data indicate that following IV 2 mcg desmopressin, 52% of the administered dose is recovered in urine by 24 hours as unchanged drug.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Elimination is described with a half-life range (3.3–3.5 hours) across intranasal doses 150–450 mcg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal impairment is associated with prolonged desmopressin elimination: terminal t1/2 rose from 3 to 9 hours after a 2 mcg injected dose (n=24 across normal to severe impairment).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal excretion is the primary elimination route stated for desmopressin acetate injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After intravenous dosing in humans, desmopressin showed a steady-state volume of distribution (Vdss) of 0.3 L.kg-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Cmax measures peak concentration; AUC0–t and AUC0–∞ quantify exposure over time to last measurable sample and extrapolated to infinity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Renal excretion is substantial: following IV dosing (2 mcg), over half the dose is recovered unchanged in urine over 24 hours, indicating limited metabolic conversion before excretion.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The excretion data state that following a 2 mcg intravenous dose, just over half the dose (52%) was recovered in urine over 24 hours as unchanged drug, indicating substantial renal elimination.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The pharmacokinetics section reports renal excretion of unchanged drug: following a 2 mcg intravenous dose, 52% of desmopressin is recovered in urine over 24 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Human intravenous pharmacokinetics report desmopressin systemic clearance (CL) of 1.4 mL.min-1.kg-1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In rat pharmacokinetic testing after intravenous administration, desmopressin showed an elimination half-life (T1/2) of 0.65 hr.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Elimination half-life is reported as 3.3 to 3.5 hours across intranasal dose levels 150 to 450 mcg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal impairment labeling states renal excretion is a major elimination route for desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Renal excretion is substantial; following 2 mcg IV dosing, about half the dose is recovered unchanged in urine over 24 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This finding is specific to a single-dose injection study with renal impairment groups and may not directly represent oral tablet pharmacokinetics.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A human pharmacokinetic report lists systemic clearance (CL) of 1.4 mL.min-1.kg-1 for CHEMBL1429 after intravenous administration, reflecting the rate of drug elimination from plasma per kg body weight.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Renal impairment prolongs desmopressin elimination: after a single 2 mcg IV dose, terminal half-life rose stepwise from 2.8 hours (normal renal function) to 4, 6.6, and 8.7 hours across mild to severe renal impairment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Median time to maximum concentration (Tmax) reflects the typical time to peak systemic exposure after dosing; here it was 1.0 h for both formulations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A renal impairment pharmacokinetic study (single-dose 2 mcg injection) reported longer terminal half-life with severe renal impairment compared with normal renal function (3 hours to 9 hours).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
Postmarketing safety reporting includes very rare hyponatremia; labeling states that untreated or improperly treated hyponatremia can be fatal.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (DDAVP) carries a risk of hyponatremia, and severe hyponatremia may progress to serious neurologic and respiratory complications or death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is associated with hyponatremia; severe hyponatremia is described as potentially fatal with serious neurologic and respiratory complications.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Desmopressin’s antidiuretic action reduces free-water excretion; if fluid intake is excessive, dilutional hyponatremia and water intoxication can occur.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a potent antidiuretic, desmopressin can promote excess water retention, resulting in dilutional hyponatremia; severe hyponatremia is described as potentially fatal.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin is a potent antidiuretic, it can precipitate dilutional hyponatremia/water intoxication; the warning states untreated hyponatremia can be fatal.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is associated with hyponatremia; severe cases may progress to neurologic and respiratory complications including seizures, coma, respiratory arrest, or death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A key safety risk is hyponatremia with desmopressin acetate injection; if severe and not promptly recognized and treated, it may progress to neurologic and respiratory complications and death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate therapy may induce hyponatremia; severe cases can progress to neurologic and respiratory complications and death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is associated with hyponatremia risk; severe hyponatremia is described as potentially life-threatening with serious neurologic and respiratory consequences.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label warns that hyponatremia is a known risk and describes potential severe consequences; it does not quantify how often this happens.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate injection may induce hyponatremia; severe cases can progress to neurologic and respiratory complications including seizures, coma, respiratory arrest, or death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a potent antidiuretic, desmopressin can reduce free-water excretion and thereby increase risk of water intoxication and hyponatremia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin limits urine output, excessive fluid intake can precipitate dilutional hyponatremia (water intoxication).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (DDAVP) is associated with hyponatremia; severe hyponatremia is described as potentially life-threatening with serious neurologic and respiratory consequences.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate may induce hyponatremia; severe hyponatremia is described as potentially fatal and associated with neurologic and respiratory complications.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin is a potent antidiuretic, it can precipitate dilutional hyponatremia (water intoxication); the warning notes potential fatality without proper diagnosis and treatment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DDAVP can cause water intoxication and/or hyponatremia, which can be fatal if not properly diagnosed and treated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This warning concerns altered absorption with chronic administration or other nasal conditions; it recommends avoiding the nasal spray route in such patients and considering other formulations/routes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A key safety risk is hyponatremia; severe cases are described as life-threatening with neurologic and respiratory complications including seizures, coma, respiratory arrest, or death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Postmarketing safety reports include very rare cases of hyponatremia in patients treated with desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin can cause low blood sodium (hyponatremia), which can be life-threatening.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
As a potent antidiuretic, desmopressin can promote free-water retention, raising the risk of hyponatremia and water intoxication.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate may induce hyponatremia (water intoxication). Severe hyponatremia is a medical emergency and can progress to neurologic complications and death.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Because desmopressin reduces free-water excretion, excessive intake can produce dilutional hyponatremia and water intoxication.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The overdose section states that excessive desmopressin acetate exposure prolongs drug action and increases risk for water retention and hyponatremia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Controlled trial adverse-event reporting notes headache as the only event ≥3%, with incidence 4% for desmopressin acetate vs 3% for placebo, and judged probably/possibly/remotely related to the study drug.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Untreated or improperly managed hyponatremia may result in death.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A key safety risk is desmopressin-induced hyponatremia; severe hyponatremia may be fatal or cause serious neurologic/respiratory outcomes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin is a potent antidiuretic, the source warns it may cause water intoxication and/or hyponatremia, and states that hyponatremia can be fatal.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
Because renal impairment affects handling of the drug and risk profile, the product lists a contraindication when creatinine clearance is under 50 mL/min.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use desmopressin injection in moderate to severe kidney impairment (creatinine clearance below 50 mL/min) due to higher hyponatremia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This limitation specifies populations where the product is not indicated; it does not explain expected outcomes if used.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This contraindication is explicitly defined by creatinine clearance threshold.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use desmopressin nasal spray if you have hyponatremia or a history of hyponatremia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because hyponatremia risk is increased, the label lists moderate to severe renal impairment (creatinine clearance below 50 mL/min) as a contraindication to desmopressin acetate injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This contraindication reflects risk management; it does not describe incidence rates.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because renal impairment increases hyponatremia risk and drug exposure, desmopressin acetate injection is contraindicated when creatinine clearance is <50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use STIMATE in patients with Type IIB von Willebrand's disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin injection should not be used in moderate to severe kidney impairment (creatinine clearance <50 mL/min) because of increased hyponatremia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is contraindicated if creatinine clearance is below 50ml/min (moderate to severe renal impairment).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Do not use desmopressin if creatinine clearance is below 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because of increased hyponatremia risk, the label contraindicates desmopressin use in moderate to severe renal impairment, defined by creatinine clearance below 50 mL/min.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
A contraindication is stated for moderate-to-severe renal impairment, operationalized as creatinine clearance <50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A stated contraindication is moderate to severe renal impairment, operationalized as creatinine clearance <50 mL/min.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 3 source records.
Because renal impairment increases hyponatremia risk and drug exposure, the product labeling lists moderate to severe renal impairment (creatinine clearance below 50 mL/min) as a contraindication for desmopressin acetate injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use DESMODA in moderate to severe kidney impairment (creatinine clearance <50 mL/min).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The nasal spray is contraindicated in renal impairment when CLcr by Cockcroft-Gault is under 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The nasal spray formulation is contraindicated in renal impairment when estimated creatinine clearance by Cockcroft-Gault is below 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling lists existing or prior hyponatremia as a contraindication to DESMODA use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source lists specific contraindicated risk groups for severe hyponatremia with desmopressin acetate: excessive fluid intake, certain intercurrent illnesses affecting fluid/electrolyte balance, and concomitant loop diuretics or systemic/inhaled glucocorticoids.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Because of increased risk (including hyponatremia risk as stated in the contraindications section), DDAVP Injection should not be used in moderate to severe renal impairment, defined here by creatinine clearance below 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use desmopressin acetate tablets in moderate to severe renal impairment (creatinine clearance below 50 mL/min).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because of renal elimination and safety risk, the nasal spray is contraindicated when estimated CLcr (Cockcroft–Gault) is <50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is contraindicated if creatinine clearance is below 50 mL/min (moderate to severe renal impairment).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This formulation is contraindicated below a Cockcroft-Gault estimated CLcr threshold of 50 mL/min due to renal impairment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindication: moderate to severe renal impairment (creatinine clearance <50 mL/min) is listed due to increased hyponatremia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use desmopressin nasal spray if creatinine clearance (Cockcroft-Gault) is less than 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is contraindicated in groups at elevated hyponatremia risk: excessive fluid intake, intercurrent illnesses that disturb fluid/electrolyte balance, and concomitant loop diuretics or systemic/inhaled glucocorticoids.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use desmopressin acetate tablets in people with hyponatremia or a past history of hyponatremia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate tablets are contraindicated if creatinine clearance is below 50 mL/min (moderate to severe renal impairment).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The contraindications include moderate to severe renal impairment (creatinine clearance below 50 mL/min), explicitly linked to increased hyponatremia risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling defines moderate to severe renal impairment as CLcr less than 50 mL/min and lists this as a contraindication.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin can promote water retention, the label lists existing or prior hyponatremia as a contraindication.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because renal impairment increases risk (including hyponatremia risk per label), DDAVP Injection is contraindicated in moderate to severe renal impairment, defined as creatinine clearance <50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The label lists a contraindication for moderate to severe renal impairment (CrCl below 50 mL/min) because hyponatremia risk is increased.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled contraindication is moderate to severe renal impairment, operationalized as creatinine clearance below 50 mL/min.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled contraindications include current or prior hyponatremia, reflecting risk of water intoxication and low serum sodium.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use DESMODA if you have hyponatremia or a history of hyponatremia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because desmopressin can precipitate dangerous hyponatremia, it is contraindicated in higher-risk settings such as polydipsia, fluid/electrolyte-imbalance illnesses, and concomitant loop diuretics or systemic/inhaled glucocorticoids.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Interactions
Source-backed product and drug interaction statements.
Because some concomitant drugs increase hyponatremia risk, combined use with desmopressin nasal spray warrants increased serum sodium monitoring frequency.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin does not undergo metabolism via the human cytochrome P450 system, suggesting CYP450-mediated metabolic interactions are unlikely via this pathway.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label advises that combining desmopressin acetate injection with medications that can promote water intoxication/hyponatremia warrants increased frequency of serum sodium monitoring.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The section gives examples (e.g., tricyclic antidepressants, SSRIs, NSAIDs, thiazide diuretics, carbamazepine); it does not quantify risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Drug interaction precaution: co-administration with medications associated with water intoxication/hyponatremia necessitates increased serum sodium monitoring frequency.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Co-administration with medications associated with hyponatremia risk warrants increased frequency of serum sodium surveillance.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
The labeled indication includes use as antidiuretic replacement therapy for central diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DESMODA is not indicated to treat nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For mild to moderate type I von Willebrand’s disease with factor VIII >5%, desmopressin acetate injection is indicated for perioperative hemostasis maintenance and reduction of bleeding with spontaneous/traumatic injuries.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In eligible type I von Willebrand disease (mild to moderate; factor VIII >5%), desmopressin injection is indicated to reduce bleeding episodes from spontaneous or traumatic injury.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In mild to moderate von Willebrand’s disease Type I with factor VIII >5%, DDAVP Injection is indicated for perioperative hemostasis support and for reducing bleeding episodes related to spontaneous or traumatic injury.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes antidiuretic hormone replacement in central diabetes insipidus and treatment of transient post-trauma/post-pituitary surgery polyuria and polydipsia.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
The labeled indication includes use as antidiuretic replacement therapy for central diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Nephrogenic diabetes insipidus is a labeled limitation of use: desmopressin acetate is described as ineffective and is not indicated for this condition.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled use includes management of primary nocturnal enuresis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indications include antidiuretic replacement therapy in central cranial diabetes insipidus and treatment of transient post-trauma or post-pituitary-surgery polyuria/polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In hemophilia A patients meeting factor VIII activity (>5%) and antibody criteria, desmopressin injection is indicated to support perioperative hemostasis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin is not used for nephrogenic diabetes insipidus because it is ineffective.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For nephrogenic diabetes insipidus, desmopressin acetate is stated to be ineffective and therefore not an indicated therapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Indication is restricted by baseline factor VIII activity and absence of factor VIII antibodies; the label does not quantify bleeding reduction.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states desmopressin acetate does not work for nephrogenic diabetes insipidus and is therefore not indicated for that condition.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This indication is restricted by baseline factor VIII activity (>5%) and absence of factor VIII antibodies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled use includes antidiuretic replacement therapy for central diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product labeling states DESMODA should not be used to treat nephrogenic diabetes insipidus (diabetes insipidus due to renal causes).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Desmopressin acetate injection is used as antidiuretic replacement therapy for central diabetes insipidus and for temporary excessive urination/thirst after certain head injuries or pituitary-region surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The indication specifies hemophilia A patients meeting laboratory criteria (factor VIII coagulant activity >5% and no factor VIII antibodies) for perioperative hemostasis and for reducing spontaneous/traumatic bleeding episodes (including hemarthroses, intramuscular hematomas, mucosal bleeding).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes management of primary nocturnal enuresis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin injection is used as antidiuretic replacement therapy for central diabetes insipidus and for temporary excessive urination/thirst after certain head injuries or pituitary surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In hemophilia A patients who have factor VIII coagulant activity levels greater than 5% and lack factor VIII antibodies, desmopressin acetate injection is indicated to support hemostasis around surgery and to reduce bleeding from spontaneous or traumatic events (e.g., hemarthroses, intramuscular hematomas, mucosal bleeding).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DDAVP Injection is indicated for central (cranial) diabetes insipidus and for temporary polyuria and polydipsia after head trauma or pituitary-region surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label indication includes antidiuretic replacement therapy for central (cranial) diabetes insipidus and treatment of temporary post-trauma or post-pituitary-surgery polyuria and polydipsia.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
This indication applies to mild to moderate Type I disease and requires factor VIII >5%; it does not state benefit size.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
These tablets are used for central diabetes insipidus and for temporary polyuria/polydipsia after head trauma or pituitary surgery, and they do not work for nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication is antidiuretic replacement therapy for central diabetes insipidus in adults and in pediatric patients aged 4 years and older.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes Type I von Willebrand’s disease (mild to moderate) with factor VIII >5% for perioperative hemostasis and for reducing spontaneous/traumatic bleeding episodes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Limitation of use: desmopressin acetate is stated to be ineffective for nephrogenic diabetes insipidus and therefore not indicated.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Indication includes hemophilia A with baseline factor VIII coagulant activity >5%.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This indication is limited to mild to moderate type I disease and requires factor VIII >5%; the label does not quantify clinical outcomes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DESMODA (desmopressin acetate) is indicated as antidiuretic hormone replacement for central diabetes insipidus in both adult and pediatric patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A, the indication is restricted by baseline factor VIII coagulant activity (>5%) and absence of factor VIII antibodies, with intended use for perioperative hemostasis and reducing bleeding from spontaneous/traumatic injuries.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin nasal spray is not indicated to treat nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For type I von Willebrand disease, the labeled indication specifies mild to moderate disease with factor VIII levels >5%, for perioperative hemostasis and reduction of bleeding episodes (e.g., hemarthroses, intramuscular hematomas, mucosal bleeding).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indications include antidiuretic replacement therapy for central (cranial) diabetes insipidus and treatment of temporary post-trauma/post-pituitary surgery polyuria and polydipsia.
4 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 4 source records.
The source states lack of efficacy for nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Indication: desmopressin acetate injection is used as antidiuretic replacement therapy in central diabetes insipidus and in transient post-traumatic or post-pituitary surgery polyuria/polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DESMODA is used as antidiuretic replacement therapy to manage central diabetes insipidus in adults and children.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is not indicated for severe von Willebrand’s disease type I or when an abnormal molecular form of factor VIII antigen is present.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes use as antidiuretic replacement therapy to manage central diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes antidiuretic replacement therapy for central (cranial) diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DESMODA (desmopressin acetate) is indicated as antidiuretic hormone replacement for treating central diabetes insipidus in adult and pediatric patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling states the nasal spray formulation is not indicated for treating nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes antidiuretic replacement therapy for central diabetes insipidus and management of transient post-trauma or post-pituitary surgery polyuria/polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is indicated for antidiuretic hormone replacement in central (cranial) diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indications include antidiuretic hormone replacement for central (cranial) diabetes insipidus and management of temporary polyuria/polydipsia after head trauma or pituitary-region surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DESMODA is not indicated for diabetes insipidus caused by renal resistance to vasopressin (nephrogenic diabetes insipidus).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
These tablets are used to manage primary nocturnal enuresis and can be used alone or with behavioral/non-drug approaches.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
STIMATE is indicated for some people with hemophilia A (factor VIII activity >5% and no factor VIII antibodies) to maintain hemostasis during/after surgery and to reduce certain bleeding episodes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A limitation of use states desmopressin acetate should not be used for severe Type I von Willebrand’s disease or when an abnormal molecular form of factor VIII antigen is present.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
STIMATE is indicated for some people with mild to moderate von Willebrand’s disease (Type I) (factor VIII >5%) to maintain hemostasis during/after surgery and to reduce certain bleeding episodes (including menorrhagia).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The nasal spray formulation is not indicated for nephrogenic diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin injection is indicated for central diabetes insipidus and for temporary excessive urination/thirst after head trauma or pituitary surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source lists labeled indications: antidiuretic replacement therapy in central diabetes insipidus, and management of temporary post–head trauma or post–pituitary surgery polyuria/polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A patients meeting label criteria (factor VIII coagulant activity >5% and no factor VIII antibodies), DDAVP Injection is indicated to support perioperative hemostasis and to reduce bleeding in spontaneous or traumatic episodes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin nasal spray is used as antidiuretic replacement therapy to manage central diabetes insipidus in adults and children age 4 years and older.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The indication is restricted to hemophilia A patients whose factor VIII coagulant activity is greater than 5% and who lack factor VIII antibodies, for perioperative hemostasis and reduction of bleeding episodes from injuries.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A, the indication is restricted by baseline factor VIII coagulant activity (>5%) and absence of factor VIII antibodies; labeled uses include perioperative hemostasis and reducing bleeding from spontaneous/traumatic events.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The hemophilia A indication is restricted to patients with factor VIII coagulant activity >5% and no factor VIII antibodies, for perioperative hemostasis and reduction of bleeding during spontaneous or traumatic episodes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For type I von Willebrand’s disease (mild to moderate, factor VIII >5%), desmopressin acetate injection is indicated to reduce bleeding during episodes such as hemarthroses, intramuscular hematomas, or mucosal bleeding.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The approved use stated is as replacement antidiuretic therapy for central cranial diabetes insipidus, reflecting ADH deficiency-related polyuria/polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label indication covers mild to moderate type I von Willebrand disease when factor VIII levels are greater than 5%, for perioperative hemostasis and reduction of bleeding episodes due to injuries.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is indicated for replacement antidiuretic therapy in central diabetes insipidus (a deficiency of ADH activity), including adults and pediatric patients ≥4 years.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication for desmopressin acetate injection includes antidiuretic replacement in central (cranial) diabetes insipidus and management of temporary post-trauma/post-pituitary surgery polyuria and polydipsia.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is indicated for central cranial diabetes insipidus and for temporary polyuria/polydipsia after head trauma or pituitary-region surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is not indicated for severe von Willebrand’s disease (Type I) or when there is evidence of an abnormal molecular form of factor VIII antigen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The source lists an indication for managing primary nocturnal enuresis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The injection is indicated for antidiuretic hormone replacement in central (cranial) diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In mild to moderate Type I von Willebrand’s disease with factor VIII levels greater than 5%, desmopressin acetate injection is indicated for perioperative/postoperative hemostasis and reduction of spontaneous/traumatic bleeding (including hemarthroses, intramuscular hematomas, or mucosal bleeding).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A patients meeting specified criteria (factor VIII coagulant activity >5% and no factor VIII antibodies), desmopressin acetate injection is indicated for perioperative hemostasis maintenance and reduction of bleeding with spontaneous/traumatic injuries.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The indication is restricted by factor VIII activity level and antibody status; it states intended uses but not comparative efficacy versus alternatives.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For diabetes insipidus due to renal resistance (nephrogenic DI), desmopressin acetate tablets are stated to be ineffective.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
It is indicated for central cranial diabetes insipidus and for temporary polyuria/polydipsia after head trauma or pituitary-region surgery.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin nasal spray is indicated for antidiuretic hormone replacement in central diabetes insipidus for adults and pediatric patients 4 years and older.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
For hemophilia A, the indication specifies baseline factor VIII coagulant activity >5% and absence of factor VIII antibodies, with use to maintain hemostasis perioperatively.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
If used before surgery, STIMATE should be given 2 hours before the procedure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available in fixed strengths containing 0.1 mg or 0.2 mg desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available in strengths of 0.1 mg and 0.2 mg desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The metered-dose pump is calibrated to deliver 10 mcg of desmopressin acetate per actuation (0.1 mL).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
To mitigate hyponatremia risk, the source recommends baseline confirmation of normal serum sodium and scheduled follow-up serum sodium measurements (within 7 days, ~1 month, and periodically), with intensified monitoring for older (65+) or higher-risk patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available in two labeled strengths, 0.1 mg and 0.2 mg desmopressin acetate USP.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Weight-based dosing recommends a single 150 mcg intranasal spray for patients <50 kg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Switching guidance: allow a 12-hour interval after the final intranasal desmopressin acetate dose before starting DESMODA in central diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
When switching from desmopressin nasal spray to DESMODA (central diabetes insipidus), wait 12 hours after the last nasal dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate tablets come in 0.1 mg and 0.2 mg strengths.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Timing is described using urine osmolality as the measurement basis; this does not specify clinical outcomes beyond the pharmacodynamic marker.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration route is specified as intranasal only for this formulation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Before initial administration, the intranasal spray device requires priming with five actuations.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 2 source records.
Weight-based labeled dosing recommends 300 mcg intranasal as one spray per nostril for patients ≥50 kg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
To reduce hyponatremia risk with desmopressin, baseline and early follow-up serum sodium monitoring is recommended (including at ~1 week and ~1 month), with closer surveillance in older (≥65 years) or higher-risk patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The preparation and administration specify dilution into sterile 0.9% Sodium Chloride Injection, USP, followed by slow IV infusion over 15–30 minutes.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The labeling specifies a fluid-restriction window spanning pre-dose (1 hour) through post-dose (at least 24 hours).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
To reduce hyponatremia risk, serum sodium should be normal at baseline and monitored early (within 7 days and ~1 month) and then periodically during therapy.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
To reduce risk of dilutional hyponatremia, confirm normal serum sodium prior to (re)initiating desmopressin acetate injection and restrict fluid intake peri-dose (1 hour pre-dose through 8 hours post-dose).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For preoperative hemostatic use, timing guidance is administration 30 minutes prior to the procedure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The marketed oral tablet strengths include 0.1 mg and 0.2 mg desmopressin acetate per tablet.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The tablets are taken by mouth and contain 0.1 mg or 0.2 mg desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The tablet formulation is supplied with desmopressin acetate USP content of 0.1 mg or 0.2 mg per tablet.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The formulation is an aqueous intranasal solution, meaning it is administered via the nasal route rather than orally or by injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Food timing is specified for administration: dosing should occur separated from meals by at least 1 hour before or 2 hours after food.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Metered-dose nasal spray actuation provides 0.1 mL of solution, containing 10 μg desmopressin acetate, per spray.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Limit fluid intake from 1 hour before desmopressin injection until 8 hours after.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
To mitigate hyponatremia risk, the prescribing information calls for baseline confirmation of normal serum sodium and scheduled follow-up monitoring (within 7 days, at ~1 month, and periodically), intensified in older (≥65 years) or higher-risk patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Monitoring guidance specifies baseline normal sodium and follow-up sodium checks at defined early timepoints (within 7 days; ~1 month), then periodic monitoring, intensified for older adults (≥65 years) and higher-risk patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is provided in 0.1 mg and 0.2 mg desmopressin acetate doses (USP).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available in two strengths: 0.1 mg and 0.2 mg desmopressin acetate per tablet.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Food-timing administration: dose DESMODA separated from meals by at least 1 hour before or 2 hours after eating.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration instruction: for diabetes insipidus, desmopressin acetate injection is specified to be used without dilution.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
The labeled oral tablet strengths provide 0.1 mg or 0.2 mg desmopressin acetate per tablet.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A and type I von Willebrand’s disease, give 0.3 mcg/kg IV (max 20 mcg) infused over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This limitation is specific to the nasal spray pump’s fixed delivered dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended adult intranasal dosing ranges from 10 mcg once daily to 40 mcg daily, optionally divided into two or three doses.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 2 source records.
DDAVP Tablets come in 0.1 mg and 0.2 mg strengths of desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For treatment-naïve diabetes insipidus, start desmopressin injection at 2–4 mcg per day (SC or IV) in 1–2 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Hemostatic dosing is weight-based at 0.3 mcg/kg (cap 20 mcg) delivered as an IV infusion lasting 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The metered-dose pump provides 10 mcg desmopressin per actuation (0.1 mL), supporting consistent intranasal dosing per spray.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Weight-based dosing is specified: patients ≥50 kg are recommended 300 mcg intranasally as one spray in each nostril.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Hemostasis indication dosing: desmopressin acetate 0.3 mcg/kg (actual body weight), capped at 20 mcg, delivered as an IV infusion over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pediatric (≥4 years) intranasal dosing begins at 10 mcg once daily, with titration up to 30 mcg/day; dosing may be divided into two doses (typical split 20 mcg AM/10 mcg PM).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For central diabetes insipidus, DESMODA oral dosing is initiated at 0.05 mg orally twice daily, with subsequent adjustment based on response.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial oral dosing for central diabetes insipidus starts at 0.05 mg twice daily, with later titration based on response.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for diabetes insipidus: 2–4 mcg/day of desmopressin acetate injection, administered subcutaneously or intravenously, in one or two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pediatric intranasal dosing (≥4 years) begins at 10 mcg once daily and may be titrated to a total of 30 mcg/day, given once daily or divided into 2 doses (often 20 mcg AM, 10 mcg PM).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
The device is specified to deliver fixed 150 mcg doses per actuation, constraining dosing to 150 mcg multiples.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemostatic indications in hemophilia A and Type I von Willebrand’s disease, desmopressin acetate is dosed at 0.3 mcg/kg (actual body weight), capped at 20 mcg, infused intravenously over 15 to 30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For treatment-naïve diabetes insipidus, the starting daily dose is 2 mcg to 4 mcg as 1 or 2 doses by subcutaneous or IV injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage strength of the oral solution is specified as 0.05 mg desmopressin acetate per mL (0.05 mg/mL).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For children age 4 years and older, the starting dose is 10 mcg once daily in one nostril, and can be increased up to 30 mcg per day (once daily or split into 2 doses, typically 20 mcg morning and 10 mcg night).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for diabetes insipidus specifies a total daily starting dose range (2–4 mcg/day) delivered by subcutaneous or intravenous injection in one or two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemostatic indications (hemophilia A; vWD Type I), desmopressin acetate injection dosing is weight-based at 0.3 mcg/kg (cap 20 mcg), given as an IV infusion over 15–30 minutes.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Initial dosing guidance for treatment-naïve diabetes insipidus patients is 2–4 mcg daily, delivered SC or IV, as 1 or 2 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage form/strength is stated as an aqueous solution in a multi-dose vial at 4 mcg per mL (40 mcg per 10 mL).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Weight-based dosing is recommended for hemostatic indications: 0.3 mcg/kg (actual body weight) up to 20 mcg, given as an IV infusion over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In central diabetes insipidus, initial dosing for treatment-naïve patients is 2 mcg to 4 mcg per day given subcutaneously or intravenously in one or two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Weight-based dosing for hemostatic indications: 0.3 mcg/kg (actual body weight), capped at 20 mcg, delivered as an IV infusion over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled weight-based IV infusion regimen for hemostatic indications is 0.3 mcg/kg (capped at 20 mcg) infused over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Each spray delivers 0.1 mL (10 μg).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing section specifies a weight-based IV infusion regimen for hemostatic indications: 0.3 mcg/kg (capped at 20 mcg) infused over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A and von Willebrand’s disease type I, the dose is 0.3 mcg/kg (max 20 mcg) by IV infusion over 15 to 30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose adjustments are individualized based on response per labeling; this statement reflects starting dosing only.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available in two labeled strengths: 0.1 mg and 0.2 mg desmopressin acetate per tablet.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The concentration of active ingredient in the nasal spray solution is 0.1 mg/mL desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Pediatric (≥4 years) dosing begins at 10 mcg intranasally once daily, with titration up to 30 mcg daily, optionally divided into two doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended STIMATE dose is 300 mcg intranasal for patients ≥50 kg and 150 mcg intranasal for patients <50 kg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The marketed parenteral dosage form is a sterile aqueous solution with concentration 4 mcg/mL, packaged as 40 mcg/10 mL multi-dose vials.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Each mL contains desmopressin acetate 0.1 mg (0.01%).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The concentration is 0.1 mg/mL, corresponding to 0.01% desmopressin acetate.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing guidance for treatment-naïve diabetes insipidus recommends initiating desmopressin acetate injection at 2 mcg to 4 mcg per day, given subcutaneously or intravenously as one or two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Hemostatic dosing per label: 0.3 mcg/kg (actual body weight), capped at 20 mcg, administered as an IV infusion over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing for central diabetes insipidus (treatment-naïve) with desmopressin acetate injection is 2–4 mcg/day, delivered IV or subcutaneously, once daily or split into two doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The injectable formulation is supplied as a sterile aqueous solution at 4 mcg/mL, packaged as either a single-dose vial or a 10 mL multiple-dose vial containing 40 mcg/10 mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose-response studies in diabetes insipidus reported clinically significant antidiuresis across oral doses from 0.025 mg to 0.4 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemostatic indications in hemophilia A and type I von Willebrand disease, dosing is weight-based (0.3 mcg/kg actual body weight) with a stated maximum total dose (20 mcg) and an IV infusion duration of 15 to 30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Each spray delivers 0.1 mL (10 mcg).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Weight-based dosing is specified: patients <50 kg are recommended a single 150 mcg intranasal spray.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The recommended starting dose is 0.05 mg by mouth twice daily (adults and children).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing for diabetes insipidus: 2–4 mcg/day, delivered by subcutaneous or intravenous injection, either once daily or split into two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosing guidance for diabetes insipidus specifies an initial total daily dose range (2 mcg to 4 mcg), given subcutaneously or intravenously once daily or split into two doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The recommended adult dosing range is given as 10 mcg once daily, titratable up to 40 mcg/day, with the option to divide 40 mcg into two or three daily doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended hemostatic dosing for hemophilia A and type I von Willebrand’s disease is weight-based (0.3 mcg/kg, capped at 20 mcg) given by IV infusion over 15–30 minutes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing for treatment-naïve diabetes insipidus is 2 mcg to 4 mcg per day, given IV or subcutaneously in one or two divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
For hemophilia A and type I von Willebrand disease, desmopressin injection is dosed at 0.3 mcg/kg (max 20 mcg) IV over 15–30 minutes, and if given before surgery it is given 30 minutes before the procedure.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dose–response data in diabetes insipidus report clinically significant antidiuresis with oral desmopressin acetate doses spanning 0.025–0.4 mg.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The pediatric (4 years and older) starting dose is 10 mcg once daily, with titration allowed up to 30 mcg/day; the 30 mcg/day can be divided into two doses (typically 20 mcg AM and 10 mcg PM).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for treatment-naïve diabetes insipidus specifies a total daily dose range (2–4 mcg) delivered subcutaneously or intravenously, split into 1–2 doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for diabetes insipidus specifies a 2–4 mcg/day total, delivered SC or IV in one or two divided doses, with subsequent adjustment based on response.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Initial dosing guidance for treatment-naïve diabetes insipidus: 2–4 mcg/day of desmopressin acetate injection given SC or IV, as 1–2 divided doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Studied populations
Who was represented in a study, label, or registry record.
Pediatric labeling states established safety/efficacy in children ≥3 months for hemophilia A and von Willebrand’s disease, and in those ≥12 years for diabetes insipidus.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
STIMATE safety and effectiveness have been established in children 11 months to 12 years with hemophilia A or von Willebrand’s disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
The source identifies two oral dosage forms of desmopressin—standard tablets and an oral lyophilizate referred to as MELT.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate is an ADH (arginine vasopressin) analogue designed to mimic antidiuretic hormone activity.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Desmopressin is described as a synthetic vasopressin analog.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Identity/classification: desmopressin acetate injection is described as a synthetic analog of vasopressin intended for intravenous or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled concentration is 4 mcg/mL desmopressin acetate, stated to correspond to 3.6 mcg/mL of desmopressin free base.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is described as a synthetic analogue of 8-arginine vasopressin (ADH), an endogenous antidiuretic hormone.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (DDAVP) is described as a synthetic analog of the peptide hormone vasopressin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The product provides a specific chemical identity for desmopressin acetate (a modified vasopressin analogue), including molecular weight and formula.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is a synthetic analogue of 8-arginine vasopressin (antidiuretic hormone), indicating it is designed to mimic ADH-related antidiuretic physiology.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
This metered intranasal pump is calibrated to deliver a fixed dose of desmopressin acetate: 10 mcg in 0.1 mL per actuation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is a synthetic analog of vasopressin formulated for parenteral administration (IV or subcutaneous).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate injection is a synthetic analog of vasopressin intended for administration by intravenous or subcutaneous routes.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Desmopressin in this nasal spray is an analogue of endogenous 8-arginine vasopressin (antidiuretic hormone).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The provided molecular properties list desmopressin’s formula as C46H64N14O12S2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin in this product is an ADH (arginine vasopressin) analogue designed to provide antidiuretic hormone activity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Desmopressin acetate is a synthetic analogue of endogenous arginine vasopressin (antidiuretic hormone, ADH).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Desmopressin acetate (injection) is a synthetic analog of vasopressin intended for IV or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is a synthetic analog of vasopressin formulated for intravenous or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate (oral tablets) is described as a synthetic analogue of 8-arginine vasopressin (ADH), the endogenous antidiuretic hormone.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin is identified in this source as 1-deamino-8-D-arginine vasopressin, abbreviated DDAVP.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate in STIMATE is described as a synthetic analogue of endogenous 8-arginine vasopressin, an antidiuretic pituitary hormone.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is described as a synthetic analogue of endogenous arginine vasopressin (antidiuretic hormone, ADH).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The drug is characterized as a synthetic analog of vasopressin intended for IV or SC administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
ChEMBL categorizes desmopressin’s molecule type as a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Formulation strength: DESMODA oral solution provides desmopressin acetate at 0.05 mg/mL.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this product, desmopressin acetate is the pharmacologically active ingredient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Desmopressin acetate (injectable) is described as a synthetic analog of vasopressin intended for intravenous or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate (injection) is described as a synthetic analog of vasopressin intended for IV or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (nasal spray solution) is described as a synthetic analog of 8-arginine vasopressin (antidiuretic hormone, ADH).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
DesST is a diagnostic stimulation test using desmopressin intended to help identify Cushing disease.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is described as a synthetic analog of vasopressin intended for administration by intravenous or subcutaneous routes.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (DDAVP Tablets) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is an ADH (arginine vasopressin) analogue designed to mimic antidiuretic hormone activity.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
The peptide 1-desamino-8-D-arginine vasopressin (dDAVP) was administered to mice as part of an 8-week experimental model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate tablets are a synthetic version of the natural pituitary hormone 8-arginine vasopressin (ADH).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin is classified as a peptide ligand (Ligand ID: 2182).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate injection is a synthetic analog of vasopressin intended for intravenous or subcutaneous administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is described as a synthetic analog of vasopressin formulated for parenteral administration (intravenous or subcutaneous routes).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin acetate is described as a synthetic analog of vasopressin, formulated for parenteral administration (intravenous or subcutaneous).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The oral tablet formulation is available with desmopressin acetate USP as the active ingredient in 0.1 mg or 0.2 mg per tablet strengths.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Desmopressin (dDAVP) is described as a synthetic analog of the endogenous peptide hormone arginine vasopressin (AVP).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Additional research & classification gaps
31 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (31)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A dose comparison showed greater BMBT reduction at 1.8 µg/kg than at 0.6 µg/kg, indicating dose responsiveness on BMBT at 30 minutes.
Research context only—not evidence of a treatment effect.
- Effect of desmopressin on buccal mucosal bleeding time in healthy dogs.
and in the 1.8 µg/kg group than in the 0.6 µg/kg group (p< 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract lists a combined dexamethasone–DDAVP dynamic test and characterizes it as a robust and practical alternative approach for this diagnostic differentiation.
Research context only—not evidence of a treatment effect.
- Differential diagnosis between endogenous Cushing´s syndrome and pseudo-Cushing.
the combined dexamethasone-DDAVP test, offering a robust and practical alternative
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In evaluating ACTH-dependent Cushing's syndrome, desmopressin is included among dynamic endocrine tests whose interpretation is emphasized as part of a composite diagnostic assessment rather than a single definitive test.
Research context only—not evidence of a treatment effect.
- Differential diagnosis of ACTH-dependent Cushing's syndrome: Biochemical, imaging, and predictive approaches.
For dynamic tests, we summarize indications and interpretation of CRH, desmopressin, and high-dose dexamethasone suppression, highlighting their value as composites rather than stand-alone arbiters.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within-group analysis showed DDAVP at 1.2 and 1.8 µg/kg increased FVIII antigen over time from baseline to 60 minutes.
Research context only—not evidence of a treatment effect.
- Effect of desmopressin on buccal mucosal bleeding time in healthy dogs.
and increased from baseline to 60 minutes in the 1.2 and 1.8 µg/kg groups (p< 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin is used as an established therapy for nocturia attributable to nocturnal polyuria.
Research context only—not evidence of a treatment effect.
- Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2020-2023).
Desmopressin is an established treatment for nocturia due to nocturnal polyuria.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with saline, intravenous bolus DDAVP at 5 microg, 10 microg, and 15 microg produced significantly larger ACTH maximum increments from baseline; the maximal ACTH response was observed at 10 microg.
Research context only—not evidence of a treatment effect.
- ACTH and cortisol release following intravenous desmopressin: a dose-response study.
The ACTH response to 5, 10 and 15 microg DDAVP was significantly greater than saline at all three doses, whilst maximal responses were seen at 10 microg.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the context of dynamic testing for distinguishing Cushing’s syndrome from pseudo-Cushing’s/non-neoplastic hypercortisolism, the DDAVP test is characterized as highly specific (without numeric specificity provided).
Research context only—not evidence of a treatment effect.
- Differential diagnosis between endogenous Cushing´s syndrome and pseudo-Cushing.
and demonstrates high specificity
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Because of its antidiuretic properties, desmopressin is used clinically in polyuric conditions such as primary nocturnal enuresis, nocturia, and diabetes insipidus.
Research context only—not evidence of a treatment effect.
- Desmopressin 30 years in clinical use: a safety review.
The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
At 60 minutes post-dose, DDAVP at 1.8 µg/kg increased FVIII antigen (FVIII:Ag) relative to control under the study conditions.
Research context only—not evidence of a treatment effect.
- Effect of desmopressin on buccal mucosal bleeding time in healthy dogs.
FVIII:Ag levels at 60 minutes were significantly higher in the 1.8 µg/kg group than in the control group (p< 0.05)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Model validation is reported as excellent agreement between the two-parameter kinetic model and experimental data for three desamino neurohypophyseal hormone analogues, including desmopressin.
Research context only—not evidence of a treatment effect.
- pubmed-42593195
The model shows excellent agreement with experimental data for three desamino analogues of neurohypophyseal hormones: atosiban, desmopressin, and desaminooxytocin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For desmopressin ODTs in this caregiver survey, perceived usability differed by task: management was rated as easy, while preparation and administration were rated as difficult.
Research context only—not evidence of a treatment effect.
- Evaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.
Desmopressin (D) was easy to manage but difficult to prepare and administer.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Measured as maximum increment from baseline, cortisol response was significantly greater than saline at 10 microg and 15 microg DDAVP, while 5 microg did not show a significantly greater cortisol response than saline.
Research context only—not evidence of a treatment effect.
- ACTH and cortisol release following intravenous desmopressin: a dose-response study.
The cortisol responses to 10 and 15 microg DDAVP doses, but not 5 microg, were significantly greater than following saline.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The review characterizes the DDAVP evidence base in antiplatelet-associated tICH as limited in quantity and heterogeneous across studies.
Research context only—not evidence of a treatment effect.
- Desmopressin for antiplatelet-associated traumatic intracranial hemorrhage: A systematic review.
Evidence for DDAVP in antiplatelet-associated tICH is limited and heterogeneous.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
DDAVP is stated to have vasodilatory activity.
Research context only—not evidence of a treatment effect.
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
It also has a vasodilatory action.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
DDAVP is reported to increase plasma concentrations of von Willebrand factor, factor VIII, and tissue plasminogen activator.
Research context only—not evidence of a treatment effect.
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
DDAVP induces an increase in plasma levels of von Willebrand factor (VWF), coagulation factor VIII (FVIII), and tissue plasminogen activator (t-PA).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin acetate is a synthetic analogue of arginine vasopressin, an endogenous antidiuretic hormone.
Research context only—not evidence of a treatment effect.
- Desmopressin 30 years in clinical use: a safety review.
Desmopressin acetate is the synthetic analogue of the antidiuretic hormone arginine vasopressin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ChEMBL, desmopressin is indexed under the identifier CHEMBL1429.
Research context only—not evidence of a treatment effect.
- DESMOPRESSIN
ChEMBL ID: CHEMBL1429
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin (DDAVP) is described as a synthetic analogue of arginine vasopressin (AVP).
Research context only—not evidence of a treatment effect.
- ACTH and cortisol release following intravenous desmopressin: a dose-response study.
Desmopressin (DDAVP) is a synthetic analogue of AVP
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source identifies two PubChem compound IDs associated with desmopressin: CID 16051933 and CID 5311065.
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
PubChem also includes the following structures for desmopressin: ( CID 16051933 and CID 5311065 ).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL lists the preferred molecule name for CHEMBL1429 as DESMOPRESSIN.
Research context only—not evidence of a treatment effect.
- DESMOPRESSIN
Preferred name: DESMOPRESSIN
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The provided synonym list includes Desmopresina as an alternative name for desmopressin.
Research context only—not evidence of a treatment effect.
- DESMOPRESSIN
Desmopresina; Desmopressin; Desmopressine; H01BA02; Ser-120; Ser120
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The synonym list includes Desmopressine as an alternate name for desmopressin.
Research context only—not evidence of a treatment effect.
- DESMOPRESSIN
Desmopresina; Desmopressin; Desmopressine; H01BA02; Ser-120; Ser120
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin is described as a synthetic analogue of arginine vasopressin (AVP).
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
Synthetic analogue of AVP.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states that aquaporin-2 can be released into urine packaged within urinary extracellular vesicles, indicating uEVs as a route for urinary AQP2 excretion.
Research context only—not evidence of a treatment effect.
- pubmed-42345393
AQP2 is excreted into urine via urinary extracellular vesicles (uEVs).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states that the mechanism by which DDAVP affects plasma factor VIII (FVIII) levels has not yet been clarified.
Research context only—not evidence of a treatment effect.
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
The mechanism of action of DDAVP on FVIII plasma levels remains to be elucidated.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source states that AVP is a companion regulator of CRH in controlling ACTH synthesis and secretion from pituitary corticotroph cells.
Research context only—not evidence of a treatment effect.
- ACTH and cortisol release following intravenous desmopressin: a dose-response study.
AVP, the companion regulator of corticotrophin-releasing hormone (CRH) in the control of ACTH synthesis and release from the pituitary corticotrophs.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Desmopressin is described as having antidiuretic properties (reducing urine output).
Research context only—not evidence of a treatment effect.
- Desmopressin 30 years in clinical use: a safety review.
The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
To assess changes over time in prescription rates, the analysis used Poisson regression models incorporating a log-population offset.
Research context only—not evidence of a treatment effect.
- Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2020-2023).
Temporal trends were evaluated using Poisson regression models with log-population offset.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states that DDAVP’s cellular mechanism of action is not completely characterized despite extensive clinical use.
Research context only—not evidence of a treatment effect.
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
In spite of its extensive clinical use, its cellular mechanism of action remains incompletely understood.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using hybrid density functional theory (PBE0-D3BJ/def2-TZVP/PCM(DMF)), the work defines an intramolecular SN2-type cyclization mechanism for S–S bond closure during iodine-mediated oxidation and indicates it is kinetically competitive with a second cysteine oxidation step.
Research context only—not evidence of a treatment effect.
- pubmed-42593195
Herein, we employ hybrid density functional theory methods (PBE0-D3BJ/def2-TZVP/PCM(DMF)) to establish the intramolecular SN2-cyclization mechanism and demonstrate that it closely competes with a second cysteine oxidation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Based on the proposed mechanism, the authors develop a two-parameter kinetic model that predicts optimal iodine stoichiometry for intramolecular disulfide (S–S) closure across peptides with different ring sizes and structures.
Research context only—not evidence of a treatment effect.
- pubmed-42593195
Based on this mechanistic insight, we develop a two-parameter kinetic model predicting the optimal iodine stoichiometry for S-S bond closure in peptides of varying ring size and structure.
Safety + tolerability
Risks, organized for scanning.
Nocdurna carries a boxed warning for potentially life-threatening hyponatremia and requires normal baseline sodium plus scheduled monitoring. [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
Contraindications
- Hyponatremia or history of hyponatremia
- Polydipsia
- Use with loop diuretics or systemic/inhaled glucocorticoids for Nocdurna
- Moderate-to-severe renal impairment for selected products
- SIADH or fluid-overload states
Common effects
- Headache
- Hyponatremia or decreased sodium
- Dizziness
- Dry mouth
- Nasal symptoms for intranasal products
Serious risks
- Severe hyponatremia, seizure, coma, or death
- Fluid retention
- Thrombotic events in selected hemostatic contexts
- Blood-pressure changes
- Medication errors across formulations
Structured from current product labeling [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| DDAVP | Tablet, nasal, or injection depending on product | Central diabetes insipidus and selected bleeding indications are route-specific. | [20]Published evidence snapshotThese highlights do not include all the information needed to use DDAVP Injection® safely and effectively. See full prescribing information for DDAVP Injection.DDAVP (desmopressin acetate) injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978dailymed · T1 |
| Nocdurna | Sublingual tablet | Nocturia due to nocturnal polyuria in selected adults. | [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements. |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Oral, sublingual, intranasal, subcutaneous, or intravenous depending on product and indication. Fluid restriction and sodium monitoring can be critical. [1]Regulatory labelNocdurna prescribing informationDailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
Research status + gaps
What still needs better answers.
1311 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (662), assurance_score_below_0.72 (544), current_regulatory_source_required (368), evidence_scope (292), extraction_ambiguity (668), high_risk_requires_regulatory_or_two_independent_sources (617), no_direct_support (1183), proposal_not_staged (18)
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelNocdurna prescribing informationOpen ↗
DailyMed label with boxed warning for hyponatremia and sodium-monitoring requirements.
- 2Literature indexEvery PubMed result for desmopressinOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 3Trial registryEvery registered study for desmopressinOpen ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.
- 4Chemical recorddesmopressin chemical recordOpen ↗
PubChem compound search from the National Library of Medicine.
- 5Published evidence snapshotChEMBL activities for CHEMBL1429Open ↗
chembl-activities · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 6Published evidence snapshotDESMOPRESSINOpen ↗
chembl-molecule · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 7Published evidence snapshotDesmopressin Acetate Tablets8472121/1222Rx onlyOpen ↗
dailymed · T1
Published 2025-11-13 · retrieved 2026-08-28T12:18:09Z - 8Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2024-03-22 · retrieved 2026-09-09T08:36:24Z - 9Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2025-10-23 · retrieved 2026-09-01T08:37:10Z - 10Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2025-07-23 · retrieved 2026-09-05T08:43:42Z - 11Published evidence snapshotDesmopressin Acetate InjectionOpen ↗
dailymed · T1
Published 2019-11-30 · retrieved 2026-08-25T11:03:07Z - 12Published evidence snapshotDesmopressin Acetate TabletsRx onlyOpen ↗
dailymed · T1
Published 2024-03-25 · retrieved 2026-09-09T08:36:24Z - 13Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2025-10-24 · retrieved 2026-09-01T08:37:10Z - 14Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-01-23 · retrieved 2026-08-28T12:18:09Z - 15Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2022-10-12 · retrieved 2026-09-09T08:36:24Z - 16Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2022-10-12 · retrieved 2026-09-09T08:36:24Z - 17Published evidence snapshotThese highlights do not include all the information needed to use DESMODA safely and effectively. See full prescribing information for DESMODA.DESMODATM(desmopressin acetate) oral solutionInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-03-02 · retrieved 2026-08-18T22:04:50Z - 18Published evidence snapshotDesmopressin Acetate TabletsRx onlyOpen ↗
dailymed · T1
Published 2025-01-31 · retrieved 2026-09-05T08:43:42Z - 19Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION, USP safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION, USP.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-08-27 · retrieved 2026-09-05T08:43:42Z - 20Published evidence snapshotThese highlights do not include all the information needed to use DDAVP Injection® safely and effectively. See full prescribing information for DDAVP Injection.DDAVP (desmopressin acetate) injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2022-09-28 · retrieved 2026-08-18T22:04:52Z - 21Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSION ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-06-19 · retrieved 2026-08-25T08:39:52Z - 22Published evidence snapshotDDAVP® Tablets (desmopressin acetate)Open ↗
dailymed · T1
Published 2021-02-03 · retrieved 2026-08-25T11:03:08Z - 23Published evidence snapshotDesmopressin Acetate Tablets, 0.1 mg and 0.2 mgOpen ↗
dailymed · T1
Published 2019-06-28 · retrieved 2026-08-18T22:04:58Z - 24Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN NASAL SPRAY SOLUTION safely and effectively. See full prescribing information for DESMOPRESSIN NASAL SPRAY SOLUTION.DESMOPRESSIN nasal spray solutionInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2025-06-19 · retrieved 2026-08-21T17:03:42Z - 25Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSION ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-03-16 · retrieved 2026-08-18T22:04:56Z - 26Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN NASAL SPRAY SOLUTION safely and effectively. See full prescribing information for DESMOPRESSIN NASAL SPRAY SOLUTION.DESMOPRESSIN nasal spray solutionInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2021-09-01 · retrieved 2026-08-21T17:03:42Z - 27Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION USP safely and effectively.See full prescribing information for DESMOPRESSIN ACETATE INJECTION USP.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2025-02-19 · retrieved 2026-09-05T08:43:42Z - 28Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION USP safely and effectively.See full prescribing information for DESMOPRESSIN ACETATE INJECTION USP.DESMOPRESSIN ACETATE injection, for intravenous or subcutaneous useInitial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2024-09-27 · retrieved 2026-09-09T08:36:24Z - 29Published evidence snapshotDesmopressin AcetateNasal Solution, 0.01%Open ↗
dailymed · T1
Published 2011-02-18 · retrieved 2026-08-25T11:03:08Z - 30Published evidence snapshotDesmopressin Acetate TabletsRx onlyOpen ↗
dailymed · T1
Published 2024-12-06 · retrieved 2026-09-05T08:43:42Z - 31Published evidence snapshotDesmopressin Nasal Spray Solution, USP 0.01%Open ↗
dailymed · T1
Published 2018-10-25 · retrieved 2026-08-25T11:03:09Z - 32Published evidence snapshotThese highlights do not include all the information needed to use DESMOPRESSIN ACETATE INJECTION safely and effectively. See full prescribing information for DESMOPRESSIN ACETATE INJECTION.DESMOPRESSION ACETATE injection, for intravenous or subcutaneous use Initial U.S. Approval: 1978Open ↗
dailymed · T1
Published 2026-06-22 · retrieved 2026-08-25T08:39:52Z - 33Published evidence snapshotDesmporessin Acetate Tablets 0.1 mg, 0.2 mgOpen ↗
dailymed · T1
Published 2025-11-07 · retrieved 2026-09-01T08:37:10Z - 34Published evidence snapshotDesmopressin Acetate TabletsRx onlyOpen ↗
dailymed · T1
Published 2026-04-23 · retrieved 2026-08-25T08:39:52Z - 35Published evidence snapshotDesmopressin Acetate TabletsOpen ↗
dailymed · T1
Published 2026-01-01 · retrieved 2026-08-28T12:18:09Z - 36Published evidence snapshotThese highlights do not include all the information needed to useSTIMATE®safely and effectively.See full prescribing information forSTIMATE.STIMATE(desmopressin acetate)nasal sprayInitial U.S. Approval:1978Open ↗
dailymed · T1
Published 2026-07-22 · retrieved 2026-08-25T08:39:52Z - 37Published evidence snapshotOpen‐Label, Balanced, Randomized, Single‐Dose, Three‐Treatment, Three‐Sequence, Three‐Period, Three‐Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral SolutionOpen ↗
doi · T6
Published 2026-08-01 · retrieved 2026-09-04T19:07:54Z - 38Published evidence snapshotEffect of desmopressin on bleeding during endoscopic sinus surgery: A randomized clinical trialOpen ↗
doi · T6
Published 2022-06-24 · retrieved 2026-09-08T21:46:02Z - 39Published evidence snapshotIUPHAR ligand commentaryOpen ↗
iuphar-comments · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 40Published evidence snapshotIUPHAR interactions for desmopressinOpen ↗
iuphar-interactions · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 41Published evidence snapshotdesmopressinOpen ↗
iuphar-ligand · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 42Published evidence snapshotACTH and cortisol release following intravenous desmopressin: a dose-response study.Open ↗
pubmed · T2
Published 1999-11-01 · retrieved 2026-09-09T18:01:30Z - 43Published evidence snapshotCellular mechanisms of the hemostatic effects of desmopressin (DDAVP).Open ↗
pubmed · T3
Published 2003-04-01 · retrieved 2026-09-09T18:01:31Z - 44Published evidence snapshot[Clinical evaluation of desmopressin (DDAVP) in diabetes insipidus: solution vs tablets].Open ↗
pubmed · T3
Published 1992-01-01 · retrieved 2026-09-08T21:46:03Z - 45Published evidence snapshotDesmopressin 30 years in clinical use: a safety review.Open ↗
pubmed · T3
Published 2007-09-01 · retrieved 2026-09-09T21:42:16Z - 46Published evidence snapshotDesmopressin administration in children with central diabetes insipidus: a retrospective review.Open ↗
pubmed · T3
Published 2013-01-01 · retrieved 2026-09-09T21:42:16Z - 47Published evidence snapshotRetrospective Assessment of Desmopressin Effectiveness and Safety in Patients With Antiplatelet-Associated Intracranial Hemorrhage.Open ↗
pubmed · T3
Published 2019-12-01 · retrieved 2026-09-09T21:42:16Z - 48Published evidence snapshotCentral Diabetes Insipidus as a Rare Cause of Polyuria.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-09-09T08:36:24Z - 49Published evidence snapshotCase Report of Acute Severe Hyponatremia Induced by Desmopressin Administration During Chemotherapy.Open ↗
pubmed · T3
Published 2026-03-01 · retrieved 2026-09-05T08:43:42Z - 50Published evidence snapshotEffect of Preprocedural Desmopressin on Complications after Kidney Biopsy: A Systematic Review and Meta-Analysis.Open ↗
pubmed · T2
Published 2026-07-01 · retrieved 2026-08-25T08:39:52Z - 51Published evidence snapshotMulti-center comparison of corticotropin releasing hormone vs. desmopressin stimulation responses in inferior petrosal sinus sampling for Cushing's disease.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-25T08:39:52Z - 52Published evidence snapshotDesmopressin for antiplatelet-associated traumatic intracranial hemorrhage: A systematic review.Open ↗
pubmed · T2
Published 2026-07-01 · retrieved 2026-08-25T08:39:52Z - 53Published evidence snapshotReduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration.Open ↗
pubmed · T3
Published 2026-03-23 · retrieved 2026-09-05T08:43:42Z - 54Published evidence snapshotEvaluation of Epithelial Integrity in Human Precision-Cut Kidney Slices.Open ↗
pubmed · T3
Published 2026-04-01 · retrieved 2026-09-05T08:43:42Z - 55Published evidence snapshotPreoperative Intravenous Desmopressin and Perioperative Blood Loss in Patients Undergoing Major Spine Surgery : Preoperative Intravenous Desmopressin and Perioperative Blood Loss in Spine Surgery Patients.Open ↗
pubmed · T3
Published 2025-01-01 · retrieved 2026-09-09T08:36:24Z - 56Published evidence snapshotEvaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-09T08:36:24Z - 57Published evidence snapshotNationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2020-2023).Open ↗
pubmed · T3
Published 2026-05-01 · retrieved 2026-09-01T08:37:10Z - 58Published evidence snapshotDifferential diagnosis between endogenous Cushing´s syndrome and pseudo-Cushing.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:43:42Z - 59Published evidence snapshotDifferential diagnosis of ACTH-dependent Cushing's syndrome: Biochemical, imaging, and predictive approaches.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:43:42Z - 60Published evidence snapshotRoles of Del-1 in effects of hyponatremia on muscle and bone in mice.Open ↗
pubmed · T3
Published 2026-10-01 · retrieved 2026-08-17T23:10:15Z - 61Published evidence snapshotGinkgo biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis: A randomized controlled trial.Open ↗
pubmed · T2
Published 2026-10-01 · retrieved 2026-09-09T08:36:24Z - 62Published evidence snapshotLower Cutoffs Improve the Diagnostic Performance of Desmopressin-Stimulated Bilateral Inferior Petrosal Sinus Sampling for Cushing Disease: A Prospective Cohort Study.Open ↗
pubmed · T3
Published 2026-06-24 · retrieved 2026-08-25T08:39:52Z - 63Published evidence snapshotpubmed-42345393Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 64Published evidence snapshotEfficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis.Open ↗
pubmed · T3
Published 2026-05-14 · retrieved 2026-08-28T12:18:09Z - 65Published evidence snapshotEffect of desmopressin on buccal mucosal bleeding time in healthy dogs.Open ↗
pubmed · T2
Published 2026-05-01 · retrieved 2026-09-01T08:37:10Z - 66Published evidence snapshotComparison of the efficacy of two different desmopressin formulations in pediatric patients with nocturnal enuresis: a retrospective observational study.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-09-05T08:43:42Z - 67Published evidence snapshotSustained remission of chronic post-traumatic arginine vasopressin deficiency despite absent posterior pituitary bright spot on MRI: a case series.Open ↗
pubmed · T3
Published 2026-07-11 · retrieved 2026-09-05T08:43:42Z - 68Published evidence snapshotHormone replacement before brain death increases organ donation rate after catastrophic brain injury: An EAST multicenter trial.Open ↗
pubmed · T3
Published 2026-07-17 · retrieved 2026-08-21T17:03:42Z - 69Published evidence snapshotpubmed-42488369Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 70Published evidence snapshotEvaluation of desmopressin stimulation test specificity in healthy volunteers.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-21T17:03:42Z - 71Published evidence snapshot[Pregnancy and thirst, a remarkable duo].Open ↗
pubmed · T3
Published 2026-07-30 · retrieved 2026-08-21T17:03:42Z - 72Published evidence snapshotStructural control and resilience in the oxytocin molecular graph: A graph-theoretic framework for critical atom and bond identification with comparative validation across cyclic peptides.Open ↗
pubmed · T3
Published 2026-11-01 · retrieved 2026-09-07T08:44:20Z - 73Published evidence snapshotpubmed-42593195Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 74Published evidence snapshotBeyond Classical Diabetes Insipidus: A Retrospective Case Series Illustrating the Diagnostic Complexity and Diverse Etiologies of Polyuria-Polydipsia Syndrome.Open ↗
pubmed · T3
Published 2026-07-01 · retrieved 2026-08-21T17:03:42Z